Gregory Scott Stein
Tulane University is actively seeking commercial entities to further develop and commercialize novel compounds which effectively remove thrombin and trypsin from the human blood stream, thereby inhibiting tumor growth and inflammation.
This technology has been tested extensively in vitro, with results strongly supporting the efficacy of the compounds. Laboratory work is ongoing to produce more effective species of these compounds.
Tulane Technology Transfer and Intellectual Property Development, New Orleans, LA 70112 504-988-6962 email@example.com